Clinical Trial

RAT-HEMATO : Return to Work After Malignant Hemopathy

Study acronym: RAT-HEMATO
Recruiting
View on ClinicalTrials.gov →
Summary
Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-11
notable Primary completion pushed: 2027-04-01 -> 2027-09 2026-08-11
minor Completion pushed: 2027-04-01 -> 2027-09 2026-08-11
Trial Details
NCT Number NCT06262789
Lead Sponsor University Hospital, Angers
Conditions Leukemia, Lymphoma, Multiple Myeloma
Enrollment 264 participants
Start Date 2024-09-27
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-10